New combo therapy shows promise for rare liposarcoma
NCT ID NCT04794127
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 study tested whether adding pioglitazone (a diabetes drug) to trabectedin (a chemotherapy) could help shrink or control liposarcoma, a rare cancer of fat tissue. The study included 10 patients whose tumors had stopped growing but not shrunk with trabectedin alone. Researchers measured tumor response and side effects to see if the combination was safe and effective.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
trabectedin and pioglitazone
What this could lead to
If it works, this combination could help shrink or control liposarcoma tumors that have stopped responding to trabectedin alone.
What could go wrong
This is a very small, early-phase study with only 10 participants. The results may not apply to all patients, and the combination may cause additional side effects without improving outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIPOSARCOMA, DEDIFFERENTIATED are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fondazione IRCCS Istituto Nazionale Tumori
Milan, MI, 20133, Italy